Viewing Study NCT04421560


Ignite Creation Date: 2025-12-25 @ 2:07 AM
Ignite Modification Date: 2025-12-26 @ 3:03 AM
Study NCT ID: NCT04421560
Status: RECRUITING
Last Update Posted: 2025-09-03
First Post: 2020-06-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Sponsor: Dana-Farber Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module